Cambridge Investment Research Advisors Inc. has made a $204,000 investment in CinCor Pharma, Inc. (NASDAQ:CINC)
According to the company's most recent filing with the SEC, Cambridge Investment Research Advisors Inc. acquired a new stake in ...
Tag: CINC, Analyst Rating
Morgan Stanley has raised its price target on CinCor Pharma (NASDAQ:CINC) to $30.00.
In a research note distributed to investors on Tuesday, analysts at Morgan Stanley increased their target price for CinCor Pharma ...
CinCor Pharma is the subject of unusually high option trading (NASDAQ:CINC)
On Tuesday, the volume of trading that occurred in connection with CinCor Pharma, Inc. (NASDAQ: CINC) options was significantly higher ...
Barclays now has CinCor Pharma (NASDAQ:CINC) covered.
The Fly notes that stock analysts at Barclays began covering shares of CinCor Pharma in a research note sent to ...
CinCor Pharma, Inc.’s (NASDAQ:CINC) November Short Interest Increased by 14.6%
CinCor Pharma, Inc. (NASDAQ: CINC) saw a noticeable rise in short interest in November. As of November 15th, 2,120,000 shares ...
Oppenheimer has issued an earnings estimate for CinCor Pharma, Inc. for fiscal year 2026.
Company Name: CinCor Pharma, Inc. (NASDAQ: CINC) CinCor Pharma, Inc. CinCor Pharma, Inc. In research published on Monday, November 28th, ...
CinCor Pharma (NASDAQ:CINC) is down 6% following an analyst downgrade.
The share price of CinCor Pharma, Inc. (NASDAQ: CINC) dropped by 6% on Tuesday after Morgan Stanley lowered its rating ...
Piper Sandler lowers its price target on CinCor Pharma (NASDAQ:CINC) to $53.00.
According to The Fly, analysts at Piper Jaffray lowered their target price for CinCor Pharma (NASDAQ: CINC) shares from $73.00 ...
Lifesci Capital has begun researching CinCor Pharma (NASDAQ:CINC).
According to The Fly, a research report distributed to clients and investors on Monday by Lifesci Capital indicates that the ...
Brokerages’ Average Recommendation for CinCor Pharma, Inc. (NASDAQ:CINC) is “Buy.”
According to Bloomberg Ratings, the stock of CinCor Pharma, Inc. (NASDAQ: CINC) has an average " Buy " rating from ...
